Sintx Technologies, Inc 8-K, filed Jan 30, 2020
Sintx Technologies, Inc. (SINT)
About this 8-K
Sintx Technologies, Inc filed this 8-K on January 30, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 30, 2020
SINTX Technologies, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-33624 | 84-1375299 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1885 West 2100 South
Salt Lake City, UT 84119
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (801) 839-3500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s): | Name of each exchange on which registered: | ||
| Common Stock, par value $0.01 per share | SINT | The NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01 Regulation FD Disclosure.
On January 30, 2020 the Company issued a press release with respect to a research collaboration. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release of SINTX Technologies, Inc. dated January 30, 2020 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SINTX Technologies, Inc. | ||||
| Date: | January 30, 2020 | By: | /s/ B. Sonny Bal | |
| B. Sonny Bal | ||||
| Chief Executive Officer | ||||
SINTX TECHNOLOGIES ANNOUNCES AGREEMENT TOWARD A COLLABORATION WITH NISSIN MANUFACTURING CO., LTD.
SALT LAKE CITY, UT, January 30, 2020 (GLOBE NEWSWIRE) - SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company that develops and commercializes silicon nitride for medical and non-medical applications, today announced an agreement toward establishing a collaboration framework with Nissin Manufacturing Company, Japan (“Nissin”). The companies have agreed to terms whereby Nissin and SINTX will fund research and product development activities collaboratively at a newly developed joint research center, located in Kyoto, Japan. The purpose of this collaboration is to develop new products for worldwide markets, using SINTX’s unique technology and knowledge in silicon nitride ceramics, and Nissin’s superior manufacturing technology platforms and retail channels.
Established in 1946, Nissin is a worldwide provider of many products, including precision automotive components, vertical automatic honing machines, and special purpose grinding machines, and others. The collaboration with SINTX is intended to expand Nissin’s footprint in consumer products based on aseptic polymer technologies already in production. “We were attracted to the considerable scientific evidence that SINTX has produced, attesting to the antibacterial properties of silicon nitride. Our initial focus will target products that leverage the ability of silicon nitride to resist bacterial adhesion, and to inactivate viruses, with more to follow,” said Takashi Nishikohri, CEO of Nissin. “The collaboration is structured as an open model to facilitate continued growth and strategic opportunities, and we look forward to developing a lasting and productive relationship with SINTX,” added Nishikohri-san.
“We are pleased at this external validation of our technology by a large, seasoned company such as Nissin, with its worldwide footprint. The relationship will further boost our already very productive R&D output that generated 25 published scientific reports in 2019 alone and more than 100 since 2015. The collaboration with Nissin is intended to directly apply our material science expertise toward new product development, and revenues. This is a significant move for SINTX,” said Dr. Sonny Bal, CEO and President of SINTX Technologies.
Nissin (https://www.nissin-mfg.co.jp/en/) is a privately-held company with its headquarters located in Kyotango-city, Kyoto Prefecture, Japan. The company has locations elsewhere around the world, and is a global supplier of automotive components, and precision machines to facilitate grinding and honing operations. Other Nissin group’s products include specialty polymers with bacterial resistance, ceramic components, and related product lines.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride spinal implants in its FDA registered and ISO 13485 certified manufacturing facility for CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants.
For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com
Forward-Looking Statements
This press release contains forward-looking statements, including those relating to an external agreement with another company, within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, the Company’s ability to complete its obligations under the agreement; volatility in the price of the Company’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 11, 2019, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
| Contact: | |
| SINTX Technologies | |
| 801.839.3502 | |
| IR@sintx.com |